Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Ontology highlight
ABSTRACT: Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic platform that facilitates rapid discovery of drug combinations that can overcome resistance. We established cell culture models derived from biopsy samples of lung cancer patients whose disease had progressed while on treatment with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors and then subjected these cells to genetic analyses and a pharmacological screen. Multiple effective drug combinations were identified. For example, the combination of ALK and MAPK kinase (MEK) inhibitors was active in an ALK-positive resistant tumor that had developed a MAP2K1 activating mutation, and th
SUBMITTER: Crystal AS
PROVIDER: S-EPMC4388482 | biostudies-literature | 2014 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA